Compare Stocks

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEB Hemispherx BioPharma	$0.42 -10.6%	$0.00	$1.69 ▼ $14.81	$1.03M	N/A	102,599 shs	169,268 shs
HEM Hemostemix	C$0.05 -9.1%	C$0.07	C$0.05 ▼ C$0.18	C$4.49M	0.55	40,392 shs	20,000 shs
NSCI Nanalysis Scientific	C$0.45 +6.0%	C$0.44	C$0.35 ▼ C$0.66	C$50.08M	0.82	65,347 shs	259,752 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEM Hemostemix	0.00%	-9.09%	-23.08%	-33.33%	-67.74%
NSCI Nanalysis Scientific	+13.51%	+12.00%	+6.33%	+7.69%	-30.00%

This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	C$0.00 per share	10.77	C($0.08) per share	N/A
NSCI Nanalysis Scientific	C$25.87M	1.94	C$0.05 per share	8.93	C$0.25 per share	1.78

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEB Hemispherx BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	-C$3.17M	-C$0.04	N/A	∞	N/A	N/A	N/A	-165.67%	4/23/2024 (Estimated)
NSCI Nanalysis Scientific	-C$16.96M	-C$0.17	N/A	∞	N/A	-65.57%	-47.87%	-15.68%	4/25/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A
HEM Hemostemix	N/A	N/A	N/A	N/A	N/A
NSCI Nanalysis Scientific	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEB Hemispherx BioPharma	N/A	N/A	N/A
HEM Hemostemix	N/A	0.25	0.48
NSCI Nanalysis Scientific	71.36	1.52	1.11

Ownership

Institutional Ownership

Company	Institutional Ownership
HEB Hemispherx BioPharma	N/A
HEM Hemostemix	N/A
NSCI Nanalysis Scientific	0.03%

Insider Ownership

Company	Insider Ownership
HEB Hemispherx BioPharma	N/A
HEM Hemostemix	12.15%
NSCI Nanalysis Scientific	7.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEB Hemispherx BioPharma	31	2.44 million	N/A	Not Optionable
HEM Hemostemix	N/A	89.79 million	N/A	Not Optionable
NSCI Nanalysis Scientific	249	112.54 million	N/A	Not Optionable

BPH, HEB, HEM, and NSCI Headlines

Source	Headline
	Nanalysis Announces Full Year 2023 Conference Call ca.finance.yahoo.com - April 11 at 10:39 AM
	Nanalysis Scientific Corp. Announces Director Resignation ca.finance.yahoo.com - April 10 at 10:29 AM
	AI Revolutionizes Drug Detection with Compact NMR and Machine Learning theglobeandmail.com - April 4 at 4:36 PM
	Scientists identify distinct molecular signatures for sepsis diagnosis and prognosis msn.com - March 31 at 8:59 PM
	Insider Buying: Nanalysis Scientific Corp. (CVE:NSCI) Director Acquires 80,000 Shares of Stock insidertrades.com - March 19 at 5:39 AM
	Canadian Investment Regulatory Organization Trading Halt - NSCI ca.finance.yahoo.com - March 6 at 6:23 PM
	Canadian Investment Regulatory Organization Trade Resumption - NSCI finance.yahoo.com - March 6 at 6:23 PM
	Nanalysis Scientific Corp.: Nanalysis Achieves Record Revenue in Q4 finanznachrichten.de - February 6 at 1:27 PM
	Nanalysis Scientific says Q4 revenue expected to be at least $9.3M msn.com - February 6 at 1:27 PM
	Nanalysis Achieves Record Revenue in Q4 finance.yahoo.com - February 6 at 9:43 AM
	Nanalysis Scientific Corp. Provides Update on Security Services Business finance.yahoo.com - January 30 at 8:55 AM
	Closing Bell: Nanalysis Scientific Corp flat on Thursday (NSCI) theglobeandmail.com - December 15 at 9:47 AM
	Nanalysis Scientific Corp Ordinary Shares NSCI morningstar.com - December 2 at 2:33 PM
	Nanalysis Scientific Corp.: Nanalysis Reports Third Quarter 2023 Results finanznachrichten.de - December 1 at 3:28 PM
	Nanalysis Reports Third Quarter 2023 Results finance.yahoo.com - November 29 at 7:47 PM
	Nanalysis Announces Third Quarter 2023 Conference Call finance.yahoo.com - November 15 at 9:51 AM
	Nanalysis Scientific Corp. (NSCIF) finance.yahoo.com - November 2 at 7:39 AM
	Nanalysis Scientific: Top 10 Undervalued Hardware Industry Stocks (NSCI) theglobeandmail.com - October 29 at 5:51 PM
	Stories by Chelsea Harvey scientificamerican.com - October 24 at 1:27 PM
	Nanalysis Scientific Corp.'s (CVE:NSCI) Share Price Is Matching Sentiment Around Its Revenues finance.yahoo.com - September 11 at 11:07 AM
	Nanalysis Scientific Corp.: Nanalysis Reports Second Quarter 2023 Results finanznachrichten.de - August 25 at 6:03 PM
	Echelon Wealth Partners Reaffirms Their Buy Rating on Nanalysis Scientific (NSCIF) markets.businessinsider.com - August 25 at 8:21 AM
	Nanalysis Scientific reports Q2 results seekingalpha.com - August 24 at 9:24 PM
	Nanalysis Reports Second Quarter 2023 Results finance.yahoo.com - August 24 at 4:23 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 High Short Interest Stocks Getting Squeezed With Upside To Go
April 5, 2024 9:25 AM
View 5 High Short Interest Stocks Getting Squeezed With Upside To Go
3 Stocks About to Book Gains on Building Products Demand
April 4, 2024 1:07 PM
View 3 Stocks About to Book Gains on Building Products Demand
Apple Faces DOJ Scrutiny, but Not These 3 Under the Radar Names
March 25, 2024 9:46 AM
View Apple Faces DOJ Scrutiny, but Not These 3 Under the Radar Names
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
April 15, 2024 10:16 AM
View 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1
April 9, 2024 7:44 AM
View 3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1

All Headlines

Company Descriptions

Hemispherx BioPharma

NYSEAMERICAN:HEB

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Hemostemix

CVE:HEM

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Nanalysis Scientific

CVE:NSCI

Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial